检索结果 - Shubham Pant

Refine Results
  1. 1
    Treatment of Breast Cancer With Trastuzumab During Pregnancy

    Treatment of Breast Cancer With Trastuzumab During Pregnancy 由 Shubham Pant, Mark B. Landon, Michael L. Blumenfeld, William Farrar, Charles L. Shapiro

    出版 2008
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  2. 2
    Pancreas Cancer-Associated Pain Management

    Pancreas Cancer-Associated Pain Management 由 Andrew L. Coveler, Jonathan D. Mizrahi, Bory Eastman, Smith Apisarnthanarax, Shalini Dalal, Terry A. McNearney, Shubham Pant

    出版 2021
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    Adagrasib in Advanced Solid Tumors Harboring a <i>KRAS</i><sup><i>G12C</i></sup> Mutation

    Adagrasib in Advanced Solid Tumors Harboring a <i>KRAS</i><sup><i>G12C</i></sup> Mutation 由 Tanios Bekaii‐Saab, Rona Yaeger, Alexander I. Spira, Meredith Pelster, Joshua K. Sabari, Navid Hafez, Minal Barve, Karen Velastegui, Xiaohong Yan, Aditya Shetty, Hirak Der‐Torossian, Shubham Pant

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer 由 Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martínez, Enaksha Wickremsinhe, Aaron Alan Fink, Volker Wacheck, Kathleen N. Moore

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older

    Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older 由 Jonathan D. Mizrahi, Jane E. Rogers, Kenneth R. Hess, Robert A. Wolff, Gauri R. Varadhachary, Milind Javle, Rachna T. Shroff, Linus Ho, David R. Fogelman, Kanwal Raghav, Michael J. Overman, Shubham Pant

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors

    A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors 由 Shubham Pant, Mansoor N. Saleh, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, Carla Kurkjian, Kathleen N. Moore, Julia Kazakin, Giovanni Abbadessa, Y. Wang, Y. Chen, Brian Schwartz, Luis H. Camacho

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers

    Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers 由 Mohamed A. Gouda, Helen J. Huang, Sarina A. Piha‐Paul, S. Greg Call, Daniel D. Karp, Siqing Fu, Aung Naing, Vivek Subbiah, Shubham Pant, Derek Dustin, Apostolia M. Tsimberidou, David S. Hong, Jordi Rodón, Funda Meric‐Bernstam, Filip Janků

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer

    Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer 由 Benny Johnson, Jonathan M. Loree, Alexandre A. Jácome, Shehara Mendis, Muddassir Syed, Van K. Morris, Christine M. Parseghian, Arvind Dasari, Shubham Pant, Victoria M. Raymond, Eduardo Vilar, Michael J. Overman, Bryan K. Kee, Cathy Eng, Kanwal Raghav, Scott Kopetz

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

    PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) prev... 由 L.-T. Chen, Jens T. Siveke, Andrea Wang‐Gillam, Richard Hubner, Shubham Pant, Tomislav Dragovich, Vincent Chung, David Chang, Paul J. Ross, Prasad Cooray, Niall C. Tebbutt, F. Franke, Bruce Belanger, Navreet Dhindsa, F. de Jong, Khalid Mamlouk, Daniel D. Von Hoff

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors

    A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid t... 由 Carol Aghajanian, Katherine M. Bell‐McGuinn, Howard A. Burris, Lillian L. Siu, Lee-Ann Stayner, Jennifer J. Wheler, David S. Hong, Carla Kurkjian, Shubham Pant, Ademi Santiago-Walker, Jennifer Gauvin, Joyce Antal, Joanna Opalinska, Shannon R. Morris, Jeffrey R. Infante

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies

    Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Maligna... 由 Vivek Subbiah, Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Janků, Jordi Rodón, Shubham Pant, Ecaterina E. Dumbrava, Siqing Fu, David S. Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric‐Bernstam, Aung Naing

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

    First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors 由 Todd M. Bauer, Byoung Chul Cho, Rebecca S. Heist, Lyudmila Bazhenova, Theresa L. Werner, Sanjay Goel, Dong‐Wan Kim, Douglas Adkins, Richard D. Carvajal, Ajjai Alva, Keith D. Eaton, Judy Wang, Yong Liu, Xiaohong Yan, Jamie Christensen, Saskia Neuteboom, Richard C. Chao, Shubham Pant

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers

    Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers 由 Natalie Ngoi, Tin‐Yun Tang, Catia Fava Gaspar, Dean C. Pavlick, Gregory M. Buchold, Emma L. Scholefield, Vamsi Parimi, Richard S.P. Huang, Tyler Janovitz, Natalie Danziger, Mia Levy, Shubham Pant, Anaemy Danner De Armas, David Kumpula, Jeffrey S. Ross, Milind Javle, Jordi Rodón

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer

    A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer 由 Shubham Pant, Suzanne F. Jones, Carla Kurkjian, Jeffrey R. Infante, Kathleen N. Moore, Howard A. Burris, D. Scott McMeekin, Karim A. Benhadji, Bharvin K.R. Patel, Martin Frenzel, Jonathan D. Kursar, Maciej J. Zamek‐Gliszczynski, Eunice Yuen, Edward M. Chan, Johanna C. Bendell

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

    Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma 由 Mouhammed Amir Habra, Bettzy Stephen, Matthew T. Campbell, Kenneth R. Hess, Coya Tapia, Mingxuan Xu, Jordi Rodón, Camilo Jiménez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu, Daniel D. Karp, Funda Meric‐Bernstam, Aung Naing

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma

    Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma 由 Giampaolo Perri, Laura Prakash, Wei Qiao, Gauri R. Varadhachary, Robert A. Wolff, David R. Fogelman, Michael J. Overman, Shubham Pant, Milind Javle, Eugene J. Koay, Joseph M. Herman, Michael P. Kim, Naruhiko Ikoma, Ching‐Wei D. Tzeng, Jeffrey E. Lee, Matthew H. G. Katz

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

    First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors 由 Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur E. Frankel, Peter Schmid, Kathleen N. Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, Howard A. Burris

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer

    Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer 由 Giampaolo Perri, Laura Prakash, Huamin Wang, Priya Bhosale, Gauri R. Varadhachary, Robert A. Wolff, David R. Fogelman, Michael J. Overman, Shubham Pant, Milind Javle, Eugene J. Koay, Joseph M. Herman, Michael P. Kim, Naruhiko Ikoma, Ching‐Wei D. Tzeng, Jeffrey E. Lee, Matthew H. G. Katz

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer 由 Martin H. Voss, Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla, David C. Smith, Andrés Cervantes, Igor Puzanov, Роберто Пили, Ding Wang, Shadia I. Jalal, Shubham Pant, Manish R. Patel, Rachel Neuwirth, Aaron Enke, Yaping Shou, Farhad Sedarati, Douglas V. Faller, Howard A. Burris

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Doublecortin-Like Kinase 1 Is Elevated Serologically in Pancreatic Ductal Adenocarcinoma and Widely Expressed on Circulating Tumor Cells

    Doublecortin-Like Kinase 1 Is Elevated Serologically in Pancreatic Ductal Adenocarcinoma and Widely Expressed on Circulating Tumor Cells 由 Dongfeng Qu, Jeremy Johnson, Parthasarathy Chandrakesan, Nathaniel Weygant, Randal May, Nicole M. Aiello, Andrew D. Rhim, Lichao Zhao, Wei Zheng, Stanley Lightfoot, Shubham Pant, Jeremy Irvan, Russell G. Postier, James R. Hocker, Jay S. Hanas, Naushad Ali, Sripathi M. Sureban, Guangyu An, Michael Schlosser, Ben Z. Stanger, Courtney W. Houchen

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: